Netcapital is no longer being priced as a growth story in online private capital formation. The equity is a residual claim on a subscale funding portal whose last several years of reported consulting revenue now sit under a civil fraud complaint, an auditor resignation, and a formal non-reliance notice covering multiple annual periods. The Commission filed that complaint in mid-August against the company and several affiliated individuals, alleging that sham consulting contracts with portfolio companies produced nearly fourteen million in recognized revenue. Two days later the incumbent auditor resigned and told the board that investors should stop relying on the affected statements. That sequence, not a quarterly fee print, is what now defines the stock.
The operating business underneath the legal cloud is too small to fund the franchise. Portal activity in the latest reported quarter produced only a five-figure revenue line against a multi-million operating loss, and nine-month cash used in operations ran several times the cash sitting on the balance sheet. Management already disclosed substantial doubt about continuing as a going concern, and the funding gap is being closed with original-issue-discount convertibles that become cheap common if a default lands. Nasdaq has the name on two separate clocks at once: a second bid-price cure window that runs into early next year, and a late-annual-report notice that requires a compliance plan this autumn. A reverse split is already on the table as the stated bid-price cure.
What remains for equity holders is a narrow set of observables rather than a product cycle. The next test is whether a successor auditor is named, whether a restatement of the consulting years is completed, and whether the funding-portal and broker-dealer licenses survive the enforcement case. Cecilia Lenk has already settled with the Commission and left the board; Avi Liss resigned from the audit committee citing the same complaint. If licenses stay intact and the listing is preserved, the portal can keep collecting listing and success fees. If either license or listing breaks, the purchased-technology book and the early-stage portfolio become hard to monetize for common holders. The price is paying for optionality on survival, not for demonstrated cash earnings.